Skip to main content

Fractyl Health, Inc. Common Stock (GUTS) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $0.69 (+7.58%)

Consensus Target
$5.00
Upside
+629.1%
Analysts
5
Rating
Buy(2.20)

Price Target Range

Low $2.00Consensus $5.00High $8.00
▲ Current $0.69

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy2
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Dec 19, 2025Whitney IjemCanaccord Genuity$8.00+1066.5%

GUTS vs Sector & Market

MetricGUTSHealthcare AvgLarge Cap Avg
Analyst Rating2.202.242.41
Analyst Count5818
Target Upside+629.1%+1149.5%+14.9%
P/E Ratio-0.356.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$9M$12M$18M3
2027-12-31$17M$22M$32M2
2028-12-31$92M$92M$92M4
2029-12-31$191M$252M$356M3
2030-12-31$348M$461M$651M3

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.78$-0.65$-0.574
2027-12-31$-0.82$-0.55$-0.384
2028-12-31$-0.40$-0.37$-0.342
2029-12-31$0.05$0.07$0.101
2030-12-31$0.41$0.60$0.921

Frequently Asked Questions

What is the analyst consensus for GUTS?

The consensus among 5 analysts covering Fractyl Health, Inc. Common Stock (GUTS) is Buy with an average price target of $5.00.

What is the highest price target for GUTS?

The highest price target for GUTS is $8.00, set by Whitney Ijem at Canaccord Genuity on 2025-12-19.

What is the lowest price target for GUTS?

The lowest price target for GUTS is $8.00, set by Whitney Ijem at Canaccord Genuity on 2025-12-19.

How many analysts cover GUTS?

5 analysts have issued ratings for Fractyl Health, Inc. Common Stock in the past 12 months.

Is GUTS a buy or sell right now?

Based on 5 analyst ratings, GUTS has a consensus rating of Buy (2.20/5) with a +629.1% upside to the consensus target of $5.00.

What are the earnings estimates for GUTS?

Analysts estimate GUTS will report EPS of $-0.65 for the period ending 2026-12-31, with revenue estimated at $12M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.